Alexander Azoy Sells 2,831 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,831 shares of the business’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $13.00, for a total value of $36,803.00. Following the completion of the transaction, the chief accounting officer directly owned 27,363 shares of the company’s stock, valued at approximately $355,719. The trade was a 9.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Alexander Azoy also recently made the following trade(s):

• On Friday, September 5th, Alexander Azoy sold 1,579 shares of Arcus Biosciences stock. The shares were sold at an average price of $11.88, for a total value of $18,758.52.

Arcus Biosciences Price Performance

Shares of RCUS opened at $13.47 on Thursday. The stock has a 50 day simple moving average of $10.89 and a 200 day simple moving average of $9.40. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $18.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. The firm has a market capitalization of $1.43 billion, a PE ratio of -4.25 and a beta of 0.77.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The firm had revenue of $160.00 million for the quarter, compared to analyst estimates of $32.86 million. During the same quarter in the previous year, the firm posted ($1.02) earnings per share. The business’s revenue was up 310.3% on a year-over-year basis. Sell-side analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Wall Street Zen raised Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 9th. Wells Fargo & Company dropped their target price on Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Institutional Trading of Arcus Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC boosted its position in Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after purchasing an additional 3,810 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after buying an additional 1,796 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Arcus Biosciences by 440.3% during the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after acquiring an additional 5,476 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of Arcus Biosciences in the 1st quarter valued at about $67,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.